SEARCH

SEARCH BY CITATION

References

  • 1
    The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:25602572.
  • 2
    Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991;121:12441263.
  • 3
    Pepine CJ. Why vascular biology matters. Am J Cardiol. 2001;88:5K9K.
  • 4
    Kannel WB. Blood pressure as a cardiovascular risk factor. JAMA. 1996;275:15711576.
  • 5
    Neal B, MacMahon S, Chapman N, for the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering-drugs: results of prospectively designed over views of randomised trials. Lancet. 2000;356:19551964.
  • 6
    Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study. JAMA. 1977;237:255261.
  • 7
    The 1980 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1980;140:12801285.
  • 8
    The 1984 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1984;144:10451057.
  • 9
    The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1988;148:10231038.
  • 10
    The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154183.
  • 11
    The sixth report of the Joint National Committee on pre vention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:24132446.
  • 12
    Cushman WC, Ford CE, Cutler JA, et al., for the ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393404.
  • 13
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:29812997.
  • 14
    Bakris GL, Williams M, Dworkin L, et al., for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kid Dis. 2000;36:646661.
  • 15
    Moser M. Evolution of the treatment of hypertension from the 1940s to JNC V. Am J Hypertens. 1997;10:2S8S.
  • 16
    Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA. 1996;276:18861892.
  • 17
    Messerli FH, Grossman E, Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly. A systematic review. JAMA. 1998;279:19031907.
  • 18
    RxList. The Internet Drug Index. The top 300 prescriptions for 2005 by number of US prescriptions dispensed. Available at: http://www.rxlist.com/top200.htm. Accessed May 23, 2006.
  • 19
    Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hyper tension? A meta-analysis. Lancet. 2005;366:15451553.
  • 20
    Basile J. Calcium channel blocker-based therapy reduces cardiovascular events more than a β-blockers-based regimen in the treatment of hypertension—The ASCOT Trial J Clin Hypertens (Greenwich). 2005;7:751754.
  • 21
    UK Prospective Diabetes Study Group. Tight blood pres sure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703713.
  • 22
    Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al., for the INVEST Investigators. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:28052816.
  • 23
    Bristow MR, Feldman AM, Adams KF, et al. Selective ver sus nonselective β-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? J Card Fail. 2003;9:444453.
  • 24
    Bristow MR, Nelson P, Minobe W, et al. Characterization of β1-adrenergic receptor selectivity of nebivolol and various other beta-blockers in human myocardium [abstract]. Am J Hypertens. 2005;18(pt 2):51A52A. Abstract P-121.
  • 25
    Bowman AJ, Chen CP, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol. 1994;38:199204.
  • 26
    Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an l-arginine/NO-dependent mechanism J Pharmacol Exp Ther. 1995;274:10671071.
  • 27
    Dawes M, Brett SE, Chowienczyk PJ, et al. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol. 1999;48:460463.
  • 28
    Tzemos N, Lim PO, MacDonald TM. Nebivolol revers es endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation. 2001;104:511514.
  • 29
    Ritter JM. Nebivolol: endothelium-mediated vasodilating effect J Cardiovasc Pharmacol. 2001;38(suppl 3): S13S16.
  • 30
    Bristow MR. β-adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101:558569.
  • 31
    McNeely W, Goa KL. Nebivolol in the management of essential hypertension: a review. Drugs. 1999;57:633651.
  • 32
    Van Neuten L, Dupont AG, Vertommen C, et al. A dose-response trial of nebivolol in essential hypertension J Hum Hypertens. 1997;11:139144.
  • 33
    Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol. 2003;92:344348.
  • 34
    Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:20072018.
  • 35
    Brophy JM, Joseph L, Rouleau JL. β blockers in congestive heart failure: a Bayesian meta-analysis. Ann Intern Med. 2001;134:550560.
  • 36
    Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation. 1999;100:9991008.
  • 37
    CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:913.
  • 38
    Packer M, Coats AJ, Fowler MB, et al., for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:16511658.
  • 39
    MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:20012007.
  • 40
    Flather MD, Shibata MC, Coats AJ, et al., on behalf of the SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215225.
  • 41
    Cowie MR, Fox KF, Wood DA, et al. Hospitalization of patients with heart failure: a population-based study. Eur Heart J. 2002;23:877885.
  • 42
    Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: part I: diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105:13871393.
  • 43
    Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998;98:22822289.
  • 44
    Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383393.
  • 45
    Padwal R, Straus SE, McAlister FA. Evidence-based man agement of hypertension: cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review. BMJ. 2001;322:977980.
  • 46
    Pepine CJ, Kowey PR, Kupfer S, et al., for the INVEST Investigators. Predictors of adverse outcome among patients with hypertension and coronary artery disease J Am Coll Cardiol. 2006;47:547551.
  • 47
    Houston MC, Basile J, Bestermann WH, et al. Addressing the global cardiovascular risk of hypertension, dyslipidemia, and insulin resistance in the southeastern United States. Am J Med Sci. 2005;329:276291.
  • 48
    Bestermann W, Houston MC, Basile J, et al. Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the south eastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hyper tension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. Am J Med Sci. 2005;329:292305.